Stock SCNI SCINAI IMMUNOTHERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Scinai Immunotherapeutics Ltd.

Equities

SCNI

US09073Q2049

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.4578 USD +1.74% Intraday chart for Scinai Immunotherapeutics Ltd. -1.76% -23.11%
Apr. 08 Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls MT
Apr. 08 Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scinai Immunotherapeutics CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
AQ
Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls
MT
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
PR
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services
CI
Scinai leadership to attend BIO-Europe Spring 2024
PR
Scinai Immunotherapeutics to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
AQ
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
PR
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
PR
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales
CI
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Gorlich on Louis-Jeantet Prize
AQ
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding
CI
Transcript : Scinai Immunotherapeutics Ltd. - Special Call
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
PR
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds
MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding
CI
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
PR
Scinai Announces Promising Results in a Psoriatic Human Skin Model
PR
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
AQ
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
PR
European Investment Bank extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCNI Stock
  4. News Scinai Immunotherapeutics Ltd.